Needham & Company LLC Cuts Inozyme Pharma (NASDAQ:INZY) Price Target to $12.00
Inozyme Pharma (NASDAQ:INZY – Free Report) had its price objective cut by Needham & Company LLC from $15.00 to $12.00 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating […]
Inozyme Pharma (NASDAQ:INZY – Free Report) had its price objective cut by Needham & Company LLC from $15.00 to $12.00 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating […]
